Strategic partnerships NecstGen has established and pursued multiple high-profile collaborations (Galapagos NV, Pancancer T, Astraveus) and strategic partnerships to evaluate new manufacturing capabilities and extend decentralized production. This signals openness to OEM-style and joint development opportunities that our sales team can leverage for co-development, technology transfer, and capacity-sharing deals.

CDMO scale and scope With a 4000 m2 GMP facility and full end-to-end services spanning R&D to regulatory affairs for cell and gene therapies, NecstGen presents a broad outsourcing solution. This creates cross-sell opportunities across preclinical to Phase II material production, QC/QA, and regulatory consulting for new or expanding client programs.

Therapy portfolio fit NecstGen’s focus areas include iPSC, CAR-T, NK, TIL, TCR-T, DCs, MSCs, and viral vectors (LV and AAV), plus cleanroom rental. These capabilities align with a wide range of cell and gene therapy programs seeking GMP manufacturing, process development, and flexible collaboration models.

Leadership transitions Recent CEO changes and a planned transition management role suggest a window of strategic realignment and potential new business priorities. This may present opportunities to engage during leadership onboarding to secure preferred vendor status, strategic long-term contracts, or pilot programs aligned with new direction.

Global expansion signals Publicized collaborations and events, including Dutch Bio Science Week participation and international press coverage, indicate momentum toward broader market presence. Sales outreach can target biotech and pharma companies seeking scalable, compliant cell therapy manufacturing partnerships and access to European GMP capabilities.